The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Many times, nursing homes will call doctors practically demanding some sort of medicne for delusional or combative patients. They will even suggest medicines by name. Often, these phone calls occur at 3:00 AM, and the doctor gives a quick yes to give them an answer and get back to sleep....
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
Electronic Health Records (EHR) are like a marriage, but are difficult to implement. They are expensive, time-consuming and require a paradigm shift from ALL employees of the practice. Half of all attempts fail; similar to getting married. They do save costs of transcription and filing/pulling...
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
The info that tekturna HCT works twice as well as HCTZ alone is not earth shattering. Of course it's better. That can be said of any HCT/medicine combination
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent. It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Study will be ridiculed. 1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
Immunomodulation especially with antibodies is difficult. Proteins are not as easily given and distributed through the body as low molecular weight compounds. I believe that the first drug to be effective will pave the way for many others